Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07806292) titled 'Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study' on Sept. 2.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Condition:
Unresectable Hepatocellular Carcinoma
Intervention:
Drug: anlotinib combined with benmelstobart and HAIC
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: April 28, 2025
Target Sample Size: 30
Countries of Recruitment:
China
To know more, visit https://clini...